Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Epilepsy |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 13 - Any |
| Updated: | 12/3/2017 |
| Start Date: | October 2005 |
| End Date: | June 2006 |
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy
patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
Inclusion criteria:
- Confident diagnosis of epilepsy.
- Currently on LAMICTAL and up to 2 concomitant AEDs (anti-epileptic drugs).
Exclusion Criteria:
- Females of childbearing potential cannot be on hormonal contraceptives or hormone
replacement therapy.
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials